Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 12/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.49 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.49 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950291 | 1.00 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4416752 | 0.92 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4416755 | 0.92 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL9691054 | 0.86 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL9691057 | 0.86 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL14843664 | 0.83 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL28025551 | 0.83 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL14843663 | 0.83 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4957634 | 0.83 | CYSLTR1 (0.60) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL4808042 | 0.82 | MEN1 (0.51) | CYSLTR1CYSLTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | disclosed |
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO. LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | LTC4S, CMA1, PTGIS | CYSLTR1 21/4885CYSLTR2 6/4885ABCC1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.